Asymmetric Bow-Tie Dendrimers as Versatile Platform for Drug Delivery and Diagnosis
Novel multifunctional asymmetric bow-tie dendrimers as a robust platform for drug delivery systems and diagnostic agents. Background: Dendrimers are nano-sized globular macromolecules that have been well studied as a drug delivery vehicles. Their convenient synthesis strategy, easy functionalization of the terminal end group and versatility in designing, make dendrimers such as PAMAM, a choice for drug carrier. Additionally dendrimers as macromolecular carrier have large loading capacity to achieve high concentration at tumor sites. Therefore a controlled strategy to functionalize dendrimers with multiple molecules such as targeting module, cytotoxic drug and/ or fluorescent moiety coupled with their purification strategy that achieves batch to batch consistency is critical for fully exploiting the field of dendrimer based tumor targeting. Technology Overview: To overcome the inconsistency associated with multi-functionalization of dendrimers, Researchers at Stony Brook University developed an asymmetric bow-tie dendrimer construction strategy. Using this strategy researchers developed and tested the efficacy of a novel bow-tie dendrimer, bearing a PEGylated spacer that improve solubility, vitamin as a tumor targeting module and a new generation toxoid. In summary, this technology introduces novel multifunctional asymmetric bow-tie dendrimers as a robust platform for drug delivery systems and diagnostic agents. Development Stage: _In vitro_ data is available. Advantages: - High loading capacity - Increased concentration at target sites - Allows controlled functionalization of dendrimer surface - Robust chemistry and batch-to-batch consistency Applications: - Drug delivery - Therapeutics - Imaging - Research Intellectual Property Summary: Patent application submitted Stage of Development: Utility application pending (#14/917,344) Licensing Potential: Development partner,Commercial partner,Licensing Licensing Status: The univeristy seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area. 8573 Additional Information: platform technologies,tumor targeting,drug delivery,cytotoxic,purification,vitamin,toxoid,drug delivery system,diagnostic,tumour targeting,nanoparticle drug delivery,pegylation,nano-particle,nano-micro,drug delivery compound,drug delivery platform,medical imaging,nanoparticle diagnostic,medicinal chemistry,drug nanoparticle,multifunctional dendrimers,poly amido amine,dendrimers,multifunctional,delivery system,nano,macromolecules,vehicles,modules,cytotoxic drugs,fluorescent,moieties,bearings,solubility,new,therapeutics https://stonybrook.technologypublisher.com/files/sites/0pqzve9sg3nkieahy5qw_dendrite.jpg Please note, header image is purely illustrative. Source: Khuloud T. Al-Jamal & Houmam Kafa, Wellcome Collection, CC BY 4.0.